BNP Paribas notify of 4.8% shareholding in Galapagos
May 01 2015 - 12:00PM
Mechelen,
Belgium; 1 May 2015 - Galapagos NV (Euronext: GLPG) received a
transparency notification from BNP Paribas.
Pursuant to Belgian transparency
legislation[1], Galapagos
received a transparency notification on 27 April 2015 from BNP
Paribas Investment Partners SA, BNP Paribas Asset Management SAS,
BNP Paribas Investment Partners Belgium SA, BNP Paribas Investment
Partners UK Ltd. and CamGestion SA. BNP Paribas Investment
Partners SA notified that since 22 April 2015, these entities under
its control hold 1,481201 shares, representing 4.8% of the current
30,870,677 outstanding Galapagos shares. This is compared to
the 1,538,622 shares reported in the transparency notice Galapagos
received from BNP Paribas on 5 February 2015.
About
Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action, with a
pipeline comprising three Phase 2 programs, two Phase 1 trials,
five pre-clinical studies, and 25 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed a collaboration agreement for the development and
commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos reported good activity and a favorable
safety profile at 12 weeks in both the DARWIN 1 and 2 trials in
RA. AbbVie and Galapagos also signed a collaboration
agreement in cystic fibrosis to develop and commercialize molecules
that address mutations in the CFTR gene. Potentiator GLPG1837
is currently in a Phase 1 trial, and corrector GLPG2222 is at the
pre-clinical candidate stage. GLPG1205, a first-in-class
inhibitor of GPR84 and fully-owned by Galapagos, is currently being
tested in a Phase 2 proof-of-concept trial in ulcerative colitis
patients. GLPG1690, a fully proprietary, first-in-class
inhibitor of autotaxin, has shown favorable safety in a Phase 1
trial and is expected to enter Phase 2 in idiopathic pulmonary
fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications &
IR
Tel: +31 6 2291 6240
ir@glpg.com
This release may
contain forward-looking statements, including, without limitation,
statements concerning anticipated progress, objectives and
expectations regarding the commercial potential of our product
candidates, intended product development, clinical activity timing,
and other objectives and explanations, all of which involve certain
risks and uncertainties. These statements are often, but are not
always, made through the use of words or phrases such as
"believes," "anticipates," "expects," "intends," "plans," "seeks,"
"estimates," "may," "will," "could," "stands to," "continues," "we
believe," "we intend," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any
historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking
statements. Among the factors that may result in differences are
the inherent uncertainties associated with competitive
developments, clinical trial and product development activities,
regulatory approval requirements and estimating the commercial
potential of our product candidates. Given these uncertainties, the
reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak
only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
[1]
Belgian Act of 2 May 2007 on the disclosure of major shareholdings
in issuers whose shares are admitted to trading on a regulated
market)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
HUG#1918056
Galapagos (LSE:GLPG)
Historical Stock Chart
From May 2024 to Jun 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2023 to Jun 2024